These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38530500)

  • 21. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Straatmijer T; van Gennep S; Duijvestein M; Ponsioen CIJ; Gecse KB; D'Haens GR; Löwenberg M
    Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1288-1297. PubMed ID: 33405424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.
    Parra-Izquierdo V; Frías-Ordoñez JS; Márquez JR; Juliao-Baños F; Galindo P; Cuadros C; Rojas C; Rojas N; Ardila O; Tovar-Fierro G; García-Duperly R; Vargas M; Flórez-Sarmiento C
    Gastroenterol Hepatol; 2023; 46(7):512-521. PubMed ID: 36372256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
    Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
    Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran.
    Jameshorani M; Vahedi H; Sadeghi A; Sima AR; Anushiravani A; Nateghi Beige H; Malekzadeh MM; Naserinejad S; Alatab S
    Arch Iran Med; 2021 May; 24(5):354-363. PubMed ID: 34196200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis.
    Nakamura M; Yamamura T; Maeda K; Sawada T; Mizutani Y; Ishikawa E; Ishikawa T; Kakushima N; Furukawa K; Ohno E; Kawashima H; Honda T; Ishigami M; Fujishiro M
    Nagoya J Med Sci; 2022 Feb; 84(1):169-179. PubMed ID: 35392018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure.
    Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR
    Inflamm Bowel Dis; 2024 Mar; 30(3):395-401. PubMed ID: 37209416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis.
    Gilmore R; Hilley P; Srinivasan A; Choy M; De Cruz P
    J Crohns Colitis; 2022 Jan; 16(1):166-168. PubMed ID: 34159363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review.
    Steenholdt C; Dige Ovesen P; Brynskov J; Seidelin JB
    J Crohns Colitis; 2023 Aug; 17(8):1354-1363. PubMed ID: 36860164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
    Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
    Lichtenstein GR; Rogler G; Ciorba MA; Su C; Chan G; Pedersen RD; Lawendy N; Quirk D; Nduaka CI; Thorpe AJ; Panés J
    Inflamm Bowel Dis; 2021 May; 27(6):816-825. PubMed ID: 32766762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
    Chaparro M; Garre A; Mesonero F; Rodríguez C; Barreiro-de Acosta M; Martínez-Cadilla J; Arroyo MT; Manceñido N; Sierra-Ausín M; Vera-Mendoza I; Casanova MJ; Nos P; González-Muñoza C; Martínez T; Boscá-Watts M; Calafat M; Busquets D; Girona E; Llaó J; Martín-Arranz MD; Piqueras M; Ramos L; Surís G; Bermejo F; Carbajo AY; Casas-Deza D; Fernández-Clotet A; García MJ; Ginard D; Gutiérrez-Casbas A; Hernández L; Lucendo AJ; Márquez L; Merino-Ochoa O; Rancel FJ; Taxonera C; López Sanromán A; Rubio S; Domènech E; Gisbert JP
    J Crohns Colitis; 2021 Jan; 15(1):35-42. PubMed ID: 32969471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
    N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
    Verstockt B; Volk V; Jaeckel C; Alsoud D; Sabino J; Nikolaus S; Outtier A; Krönke N; Feuerhake F; De Hertogh G; Rosenstiel P; Vermeire S; Schreiber S; Ferrante M; Aden K
    Aliment Pharmacol Ther; 2022 Jul; 56(2):282-291. PubMed ID: 35484689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
    Parra Izquierdo V; Frias-Ordoñez J; Galindo P; Romero-Sanchez C; Florez C
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S14-S15. PubMed ID: 37461974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upfront tofacitinib in patients with biological-naïve ulcerative colitis - An Indian multicentric experience.
    Giri S; Bhrugumalla S; Kamuni A; Mishra D; Pati GK; Agrawal D; Verma G; Wagh R; Chauhan S; Ingle M; Chandnani S; Jain S; Rathi PM; Shukla A; Kale A
    Indian J Gastroenterol; 2024 Feb; 43(1):237-243. PubMed ID: 37726491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study.
    Molander P; Kosunen M; Eronen H; Tillonen J; Käräjämäki A; Heikkinen M; Punkkinen J; Mattila R; Toppila I; Hölsä O; Kalpala K; Henrohn D; Af Björkesten CG
    Scand J Gastroenterol; 2024 Apr; 59(4):425-432. PubMed ID: 38156792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
    Allocca M; Catalano G; Savarino EV; Chaparro M; Levartovsky A; Michalopoulos G; Viazis N; Fousekis FS; Psistakis A; Noviello D; Nascimento CND; Caron B; Kitsou V; Bamias G; García MJ; Zacharopoulou E; Foteinogiannopoulou K; D'Amico F; Koutroubakis I; Ellul P; Tzouvala M; Peyrin-Biroulet L; Torres J; Caprioli F; Karmiris K; Theodoropoulou A; Katsanos KH; Christodoulou DK; Mantzaris GJ; Kopylov U; Gisbert JP; Danese S; Magro F; Carla F; Fiorino G
    United European Gastroenterol J; 2024 Jun; 12(5):543-551. PubMed ID: 38419274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
    J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.